Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Short Interest Down 81.5% in July

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF – Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 3,905 shares, a decrease of 81.5% from the June 30th total of 21,160 shares. Based on an average trading volume of 46 shares, the days-to-cover ratio is presently 84.9 days.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised shares of Towa Pharmaceutical to an “overweight” rating in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy”.

Get Towa Pharmaceutical alerts:

Get Our Latest Stock Report on TWAPF

Towa Pharmaceutical Price Performance

Shares of Towa Pharmaceutical stock opened at $26.00 on Friday. The firm has a fifty day moving average price of $25.53 and a 200 day moving average price of $25.40. Towa Pharmaceutical has a 1 year low of $25.71 and a 1 year high of $26.00.

Towa Pharmaceutical Company Profile

(Get Free Report)

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.

Featured Stories

• Five stocks we like better than Towa Pharmaceutical
• 2 Stocks Built to Thrive If Inflation Refuses to Fade
• Telecom Earnings Reveal a Sector That Finally Looks Healthier
• Defense Earnings Show Readiness Now and Modernization Ahead
• Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off

Receive News & Ratings for Towa Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Towa Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.